Ryvu Therapeutics S.A.
2 Sternbacha Street, 30-394 Krakow, Poland
registered in the District Court for the Krakow-Srodmiescie
in Krakow XI Division of the National Court Register
KRS number: 0000367359
VAT ID: PL6792942955

Krakow, 4th May 2023

REQUEST FOR PROPOSAL No. ABM-04052023C

In connection with the planned implementation by Ryvu Therapeutics S.A. of the project 'The conduct of a phase II, multicentre, open-label clinical trial (RIVER-81) evaluating the safety and efficacy of RVU120 in combination with venetoclax in patients with relapsed/refractory acute myeloid leukemia who have failed prior therapy with venetoclax and a hypomethylating agent' (the 'Project') under the Competition: Development of targeted or personalized medicine based on therapeutic products based on nucleic acids and small-molecule compounds ABM/2022/6 organized by the Medical Research Agency, Ryvu Therapeutics S.A. invites quotes for the execution of the following defined description of the order.

I. ORDERING PARTY

Ryvu Therapeutics S.A.
Sternbacha 2, 30-394 Krakow, Poland
EU VAT PL6792942955

II. DESCRIPTION OF THE ORDER:

This order concerns panel of diagnostic and exploratory tests of bone marrow and peripheral blood of Acute Myeloid Leukemia patients in RIVER-81 clinical study.

1. Overall Study Outline

This is a phase II, multicentre, open-label clinical trial (RIVER-81) evaluating the safety and efficacy of a selective CDK8/19 inhibitor, RVU120 in combination with BCL-2 protein inhibitor - venetoclax in patients with relapsed/refractory acute myeloid leukemia who have failed prior therapy with venetoclax in combination with the hypomethylating agent (HMA) azacytidine (Aza) or decitabine (Dec).

This clinical trial consists of three parts. It will commence with a dose-finding part (Part 1), involving sequential dose escalation to identify the highest dose levels of RVU120 + Ven considered to be safe and well tolerated, to be tested in Part 2 and Part 3 for clinical efficacy (CR+CRi+CRh).

Part 1 will follow a 3 + 3 study design and participants will be enrolled to a cohort initially comprising of 3 participants to assess safety and tolerability during the first cycle of treatment, prior to permitting RVU120 or Ven dose escalation in the next cohort

Part 2 is a preliminary enrichment phase at a selected dose level (DL) and will follow a Simon 2-stage design. Up to an additional 10 participants may also be evaluated in Part 2 in an enrichment cohort.

Part 3 involves a confirmatory cohort at a selected dose level from Part 2 to further assess the study endpoints.

2. Sponsor's Study Overall Assumptions

- Contract should start as early as possible, preferentially in June 2023.
- All process to be set-up by 15th August 2023 (before projected Study Start on 1st September 2023).

- Key project milestones and associated timelines are estimated in the Table 1, and must be used to support the proposal generation
- The numbers provided in the Tables below are estimated according to the agreed study design and enrolment rate. Sponsor reserves the right to change the number of patients, sites, samples collected and analyzed. Sponsor cannot commit to a minimum number of analyses ordered.

Table 1. ESTIMATED Project milestones and associated timelines.

Project milestones	**Timelines**
Sponsor's desired Study Start	1st September 2023
Total project duration	min. 4 months, up to 28th February 2026

- Planned study sites and estimated number of study subjects are presented in the Table 2, and must be used to support the proposal generation. Approximate Number of Subjects includes Screen Failures, drop-outs etc.

Table 2. ESTIMATED Planned study sites and estimated study size.

Study key assumptions	Unit	Total number per study (incl. overage)
Approximate number of subjects	98 patients (Part 1 18 patients Part 2 39 patients Part 3 41 patients)	98 patients (Part 1 18 patients Part 2 39 patients Part 3 41 patients)
Number of countries and sites	countries (min 2: PL and IT) sites (for Part 1 min 5)	countries (min 2: PL and IT) sites (for Part 1 min 5)

- Planned collection and sample analysis timepoints are presented in the Table 3 and should be used to support the proposal generation

Table 3. PREDICTED Planned collection and sample analysis timepoints in the study protocol.

SAMPLE ANALYSIS			**Bone Marrow**							**Blood**	
ASSAY			Cytomorphology	Cytogenetics	FISH	NGS	MRD	IMF	scRNAseq	Cytomorphology	IMF pSTAT5
STUDY VISIT											
SCREENING			X	X	X	X	P	X	P		
CYCLE 1	D1	Pre-dose								X	B
	D13±1	6-8h									B
CR/CB/PD*		Visit time	X	X	(X)	X	P	X	P	X	(X)
PREDICTED total number of samples			157	98	49	157	22	157	24	157	255

Analysis:
X – Expedited type of analysis
(X) – Optional analyses
B – batch analysis i.e. on a cycle basis
P – material preservation and storage, analysis only on selected samples/patients
*Mandatory sample to be collected at pre-dose C1D1. Additional samples will be required when there are signs of improvement or progression (to be agreed to by Ryvu and the Investigator). Expected ORR: 60%.

The proposal should state unit price for sample/sample batch analysis. Please provide cost estimation for sample vs batch analysis, wherever applicable.

Sponsor cannot commit to a minimum number of analyses ordered and reserves the right to change the number of samples to be analyzed depending on the trial progress. Analysis can only be performed upon in writing (via email) order placement from the Sponsor. Sponsor should be charged only for the ordered analyses.

3. Scope of work and tasks description

Vendor has the capability to provide following diagnostic and exploratory integrated services in RIVER-81 study:

Activity 1) Cytomorphological and cytochemical assessment of bone marrow and peripheral blood smears. Sponsor should be provided with a diagnostic report. – estimated/expected TAT around 1-3 days;

Activity 2) Chromosome banding analysis (cytogenetic) and fluorescence in-situ hybridization (FISH) if applicable based on cytogenetic findings. Sponsor should be provided with a diagnostic report. – estimated/expected TAT around 1-1.5 week;

Activity 3) NGS analyses of the genes indicated in the table below, regions of interest are indicated in a separate column

NGS should be performed with mean coverage above 1,000-fold and sensitivity of min 3%. Sponsor should be provided with a diagnostic report. – estimated/expected TAT around 10-12 days.

No.	Gene	ROI	No.	Gene	ROI
1	*ASXL1*	E12, E13	27	*NRAS*	complete coding sequence
2	*ASXL2*	E12, E13	28	*PDGFRA*	complete coding sequence
3	*BCOR*	complete coding sequence	29	*PDGFRB*	complete coding sequence
4	*BCORL1*	complete coding sequence	30	*PHF6*	complete coding sequence
5	*CALR*	E09	31	*PIGA*	complete coding sequence
6	*CBL*	complete coding sequence	32	*PPM1D*	complete coding sequence
7	*CEBPA*	complete coding sequence	33	*PTPN11*	complete coding sequence
8	*CSF3R*	E14-E17	34	*RAD21*	complete coding sequence
9	*CSNK1A1*	E03, E04	35	*RUNX1*	complete coding sequence
10	*CUX1*	complete coding sequence	36	*SETBP1*	E04
11	*DDX41*	complete coding sequence	37	*SF1*	complete coding sequence
12	*DNMT3A*	complete coding sequence	38	*SF3A1*	complete coding sequence
13	*ETNK1*	E03	39	*SF3B1*	E13-E16
14	*ETV6*	complete coding sequence	40	*SH2B3*	complete coding sequence
15	*EZH2*	complete coding sequence	41	*SMC1A*	complete coding sequence
16	*FLT3*	E14-E20	42	*SMC3*	complete coding sequence
17	*GATA1*	complete coding sequence	43	*SRSF2*	E01
18	*GATA2*	complete coding sequence	44	*STAG2*	complete coding sequence
19	*IDH1*	E04, E07	45	*TET2*	complete coding sequence
20	*IDH2*	E04, E07	46	*TP53*	complete coding sequence
21	*JAK2*	complete coding sequence	47	*UBA1*	complete coding sequence
22	*KIT*	complete coding sequence	48	*U2AF1*	E02, E06
23	*KRAS*	complete coding sequence	49	*U2AF2*	E02, E06
24	*MPL*	complete coding sequence	50	*WT1*	E07, E09
25	*NF1*	complete coding sequence	51	*ZRSR2*	complete coding sequence
26	*NPM1*	E11			

Activity 4) Immunophenotyping analysis should be performed by flow cytometry using panels as indicated in the table below.

Panel	FITC	PE	ECD	PC5.5	PC7	APC	APC-700	APC-750	PacBlue	KrOrange
Panel 1	CD64	CD34	CD4	CD33	CD19	CD56	CD15	CD14	HLA-DR	CD45
Panel 2	CD65	CD133	CD34	CD117	CD13	CD2	CD7	CD11b	CD15	CD45
Panel 3	CD71	NG2	CD38	CD34	CD61	CD36	CD117	CD235a	CD14	CD45
Panel 4	TdT	MPO		CD22	CD34	CD79a		CD3	IgM	CD45

Flow cytometric data analysis should include exclusion of doublets, gating on mononuclear cells as defined by CD45 positivity, application of Boolean gating to identify leukemic population with aberrant phenotype, identification of MRD+ cluster in CD45/SSC gate. Particular focus should be directed to maturation of leukemic cells and changes of maturational stage of non-leukemic cells during the course of treatment. Non-leukemic populations should be quantified in relation to all mononuclear cells. MFI as compared to reference populations should be determined for leukemic cells regarding expression of CD34 and CD38. If applicable, percentages of leukemic cells displaying either of the four phenotypes defined by positivity and negativity, respectively of CD34 and CD38 should be reported. Sponsor should be provided with the diagnostic report.

Flow cytometry raw data (FCS files and pdf reports on gating used during the data acquisition/analysis) should be available upon request– estimated/expected TAT around 2-4 days.

Activity 5) Minimal/Measurable Residual Disease assessment should be performed according to the algorithm from ELN MRD working Group using flow- or molecular- approach. (Heuser, Michael, et al. Blood 138.26 (2021): 2753-2767.) Sponsor should be provided with the diagnostic report. – estimated/expected TAT around 10-12 days.

Activity 6) Immunophenotyping of pSTAT5 in frozen blood samples from patients should be performed by flow cytometry using method developed and transferred from the Sponsor. Sponsor should be provided with a summary report. Flow cytometry raw data (FCS files and pdf reports on gating used during the data acquisition/analysis) should be available upon request – estimated/expected TAT around 2-5 days.

Activity 7) Single cell RNA sequencing should be performed using 10xGenomics platform Chromium X machine. Experiments should be performed using 10xGenomics 3' Gene Expression standard throughput kit (10.000 cells retrieved). Sequencing should be performed with depth 80.000 – 100.000 single-end reads/cell. Vendor should also have the possibility to perform experiments with Cell Multiplexing technology. Sponsor should be provided with a summary (quality) report and with the raw data in BCL format. Vendor should be able to provide Sponsor with fastq files upon request, these files should be prepared according to 10xGenomic procedures– estimated/expected TAT around 4-8 weeks.

Activity 8) Single cell RNA sequencing validation experiments should be performed using all technical requirements as indicated above in point 7.

Cryopreserved bone marrow mononuclear cells from two or three Acute Myeloid Leukemia patients should be analyzed as "fresh" (directly after the delivery), after 3 months of storage and after 6 months of storage. QC analysis including viability and number of cells after each timepoint should be provided. Single cell RNA sequencing should be performed on each sample separately to assess the effect of long-term storage on the transcriptome.

If results are satisfactory the multiplexing validation should be performed using samples from two additional Acute Myeloid Leukemia patients. Multiplexing approach should be validated with a head-to-head comparison to standard approach (1 sample -1 sequencing).

Sponsor should be provided with a summary (quality) report and with the raw data in BCL format. Vendor should be able to provide Sponsor with fast files upon request, these files should be prepared according to 10xGenomic procedures.

Frozen cryopreserved bone marrow mononuclear cells from Acute Myeloid Leukemia patients (not from the study) will be provided by Sponsor – estimated/expected TAT around 8-10 weeks.

If method is not available, validation will be required and should be included in the budget calculations.

Sample storage and data transfer should also be included in price.

III. CONDITIONS FOR PARTICIPATION IN THE PROCEEDINGS

III.1. Bidders that fulfill the following requirements are invited to submit the quotations:

- Bidders with the ability to work under international quality standards such as (minimum):
  - Proficiency Testing Programmes;
  - Validated QMS/RMS system;
  - ISO 15189 and ISO17025 / CLIA;
  - Valid accreditation of pathologists association (CAP, INSTAND or equivalent);
  - GLP and GCP environment/ Systems in compliance with FDA 21CFR part 11;
  - Service Provider Specification for 10x Genomics Platform at the time of first patient sample analysis;
- Bidders with the possibility to process Human BioSamples upon reception;
- Bidders with the ability for reception of samples 7 days/week;
- Bidders, who are ready to set up all processes by 15th August 2023 and perform all assays at the end of Q3/ beginning of Q4 2023.
- Bidders with documented experience in supporting hematooncological clinical trials.
  Bidders with documented experience in clinical diagnostics of leukemia and lymphoma.

The assessment of the conditions for participation in the proceedings will be made by the system meet – do not meet.

In order to confirm the fulfillment of the above conditions, the Bidders are obliged to submit a statement, which is placed in Appendix 01 to this RFP. Ordering Party may request evidence of the fulfilment upon request.

IV. PLACE, DATE AND PROCEDURE OF SUBMISSION OF PROPOSALS

IV.1. The proposal must be submitted by: **11th May 2023 at 23.59 CET**.

IV.2. The proposal must be sent via e-mail to the following address: tenders@ryvu.com. The message with the offer should refer to the RFP number indicated on the first page: **ABM-04052023C**.

IV.3. The proposal and its attachments should be prepared English.

IV.4. The proposal must be prepared in an accordance with the form constituting Appendix 01 to this RFP.

IV.5. The Bidders must provide the total price for the execution of the order (all activities including all associated costs related to kits, reagents, consumables, management and other resources and operations needed to execute contracted work). The quote must include prices given in EUR or USD.

IV.6. The proposal must include the validity period (minimum by 31th July 2023). The Ordering Party may require Bidders to agree to an extension of the quote validity period for the period of up to next 30 calendar days.

IV.7. The proposal must include the following information: Start-up timelines, Method development/validation (if applicable); Turnaround time for sample analyses and information about deliverables, data and material handling, project management according to the Appendix 01 to this RFP.

IV.8. An offer that does not meet the requirements set out above is subject to rejection, subject to the provisions on the Ordering Party's acceptance of the possibility of summoning Bidders who have not submitted the required statements, or who have not submitted registration documents or powers of attorney, or who have submitted the above-mentioned statements and documents containing errors or incomplete or raising doubts indicated by the Ordering Party, to submit, supplement or correct them within the prescribed period, or to provide explanations, unless, despite their submission, the Bidder's offer would be rejected or the procedure would be annulled. If the Bidder fails to submit, supplement or correct the above-mentioned declarations or documents within the time limit set by the Ordering Party, his offer shall be rejected. Subsequently, the committee will evaluate the offers in accordance with section V.

V. CRITERIA FOR EVALUATION OF PROPOSALS:

V.1. Offers that comply with the description of the order set out in section II. and with conditions for participation in the proceedings set out in section III. and are prepared according to procedure set out in section IV. will be accepted for the evaluation of offers. Offers that do not meet the requirements will be rejected.

V.2. **Criterion 1: Net price ("C") – max. 60 points,**

Net price ("C") considered as the total price for the execution of the order (all activities including all associated costs related to kits, reagents, consumables, management and other resources and operations needed to execute contracted work). The quote must include prices given in EUR or USD.

In order to compare the offers they shall be converted into PLN at the average exchange rate of the National Bank of Poland (NBP) prevailing on the day of closing the tender procedure indicated in section IV.1

In the Net Price criterion, points will be awarded (to two decimal places) according to the formula:

$$\text{Criterion Net price "C"} = \frac{\text{the lowest net price offered among the bids submitted}}{\text{net price of the examined offer}} \times 60 \text{ points}$$

V.3. **Criterion 2: TAT ("T") – max. 40 points,**

TAT (“T”) considered as accumulated turnaround time given in calendar days; time from arrival of the samples to the Vendor facility until the final report in total for Activities 1-8.

In the TAT criterion, points will be awarded according to below:

Accumulated TAT is greater than or equal to 172 calendar days – 0 points;
Accumulated TAT is between to 171 – 157 calendar days – 10 points
Accumulated TAT is between to 156 – 142 calendar days – 20 points
Accumulated TAT is between to 141 – 127 calendar days – 30 points
Accumulated TAT is less than or equal to 126 calendar days – 40 points.

V.4. Maximum number of points to be earned is 100,00. The Ordering Party will select as the most advantageous the offer that obtains the highest number of point.

V.5. Having to choose between quotation scored in the same number of points, the Ordering Party will call Bidders to re-present the prices.

VI. PROVISIONS OF THE AGREEMENT:

VI.1. The procedures will be concluded with the signing of a conditional agreement with the CRO selected in the proceedings. The conditional agreement with the selected CRO will come into effect upon the signing of a co-

financing agreement for the project submitted to the Competition: Development of Targeted or Personalized Medicine Based on Nucleic Acids and Small Molecule Compounds ABM/2022/6 organized by the Medical Research Agency.

VI.2. Deadline of the implementation of the agreement (completion date): The implementation of the service in the period from the agreement conclusion with the selected Bidder to the date of 28th February 2026. The Ordering Party reserves the right to change the expected date of the contract in the event of prolongation of the deadline for the completion of the Project conducted by the Ordering Party or extension of the appropriate stage of the Project, the agreement will be extended until the actual completion of the prolonged Project.

VI.3. The Ordering Party reserves the right to amend the provisions of the Agreement in relation to the content of the final tender, on the basis of which the Bidder has been selected:

a) in terms of the term of the contract – Sponsor reserves the right to change the expected date of completion of the contract following changes in the scope of the signed contract for co-financing Project (extension of the duration of the Project, extension of appropriate stages of the Project, change of research plans);

b) in terms of the order size – Sponsor cannot commit to a minimum number of analyses ordered and reserves the right to change the number of samples to be analyzed depending on the trial progress. Analysis can only be performed upon in writing (via email) order placement from the Sponsor. Sponsor should be charged only for the ordered analyses;

c) in terms of the number of patients, samples collected and analyzed, types of panel of diagnostic and exploratory tests and number and types of countries and sites – which is directly related to the conduct of a particular type of study involving oncology patients and the fact that special circumstances/ events may arise during the course of the study that could not have been foreseen earlier; Sponsor reserves the right to change the number of patients, sites, samples collected and analyzed. Sponsor cannot commit to a minimum number of analyses ordered.

VI.4. The Ordering Party allows for the possibility of awarding to the contractor selected in the course of this RFP supplementary orders, in an amount not exceeding 50% of the value of the contract specified in the agreement concluded with the contractor, while meeting the following conditions:

- such orders are consistent with the subject of the basic contract,
- the possibility of awarding such an order was provided for in the request for proposals and in the contract with the contractor,
- the total value of the supplementary order was taken into account when calculating the value of the basic order.

VII. ADDITIONAL INFORMATION

VII.1. The Bidders may ask the Ordering Party to clarify the content of this RFP. If the request for clarification of the content of the RFP was received later than by the end of 8th May 2023, the Ordering Party may provide explanations or leave the application unexamined. Questions must be sent to the following e-mail address: tenders@ryvu.com.

VII.2. Due to the need to protect business secrets, in the event of questions requiring the disclosure of confidential data, the Ordering Party reserves the right to provide explanations after signing and sending by e-mail by the Bidder the Confidential Disclosure Agreement (CDA). It is allowed to use an electronic signature (including a qualified electronic signature), a trusted signature (trusted profile). The CDA document will be made available at the request of the Bidder by e-mail. The scan of the completed and signed CDA should be sent to the indicated e-mail address: tenders@ryvu.com.

VII.3. The Ordering Party reserves the right to change the content of the RFP, including changes in the terms of the procedure. Bidders will be informed.

VII.4. The Ordering Party reserves the right to ask the Bidders at any stage of the evaluation of offers for additional information, documents, additions or explanations. The Ordering Party's contact with the Bidder will take place by e-mail indicated in the content of the offer sent by the Bidder.

VII.5. The Ordering Party reserves the right to enter into negotiations with all Bidders who have submitted an offer that meets the conditions of access (i.e. admission conditions and conditions for participation in the procedure) indicated in the content of the Request for Proposal. The negotiations will be conducted according to the following principles:

a) after the deadline for submission of offers, the Ordering Party shall notify all Bidders who have submitted tenders which are not subject to rejection of the possibility of negotiations and shall invite these Bidders to negotiate, agreeing with each Bidder on individual dates of meetings,

b) arrangements regarding the date of negotiations will be carried out by e-mail,

c) only parameters that constitute criteria for the evaluation of offers are subject to negotiations,

d) the course of negotiations shall be documented in the form of a written note signed by the negotiating teams of the Ordering Party and the Bidder,

e) within the time limit specified by the Ordering Party, the Bidder submits a modified offer, taking into account the arrangements from the negotiations. The modified offer may not contain conditions less favorable than the original offer,

f) in the event that the Bidder refuses to participate in the negotiations, the negotiations do not lead to binding arrangements or the Bidder does not submit a modified offer, the Bidder's originally submitted offer shall be evaluated,

g) Ordering party by 10 calendar days from the date of submission of the last modified offer, evaluate the offers and select the Contractor whose offer is the most advantageous.

VII.6. This RFP does not oblige the Ordering Party to conclude a contract.

VII.7. For more information, please contact Anna Dziedzicka at the following email address: tenders@ryvu.com.

ATTACHMENTS

Appendix 01 – THE PROPOSAL FORM

APPENDIX 01 TO ABM-04052023C

THE PROPOSAL FORM

Data of the Bidder Name:	
Address:	
Tax ID/EU VAT:	
Person authorized to contact the Ordering Party: name and surname:	
e-mail address:	

1. We confirm that the scope of the service offered 'Panel of diagnostic and exploratory tests of bone marrow and peripheral blood of Acute Myeloid Leukemia patients in RIVER-81 clinical study' is consistent with the description of order of the RFP no. ABM-04052023C.

Deadline of the implementation of the agreement (completion date): The implementation of the service in the period from the agreement conclusion with the selected Bidder to the date of 28th February 2026. The Ordering Party reserves the right to change the expected date of the contract in the event of prolongation of the deadline for the completion of the Project conducted by the Ordering Party or extension of the appropriate stage of the Project, the agreement will be extended until the actual completion of the prolonged Project.

2. We indicate:

Ordinal number	**Required information**	**Indication or place of indication in the offer (page, section)**
1.	Start-up timelines	
2.	Method development/validation, if applicable	
3.	Turnaround time for sample analyses	
4.	Information about deliverables	
5.	Data and material handling	
6.	Project management	

3. Statements:

- We declare that we have the ability to work under international quality standards such as (minimum):
  - Proficiency Testing Programmes;
  - Validated QMS/RMS system;
  - ISO 15189 and ISO17025 / CLIA;
  - Valid accreditation of pathologists association (CAP, INSTAND or equivalent);
  - GLP and GCP environment/ Systems in compliance with FDA 21CFR part 11;
  - Service Provider Specification for 10x Genomics Platform at the time of first patient sample analysis;
- We declare the possibility to process Human BioSamples upon reception;
- We declare the ability for reception of samples 7 days/week;
- We are ready to set up all processes by 15th August 2023 and perform all assays at the end of Q3/ beginning of Q4 2023.
- We have documented experience in supporting hematooncological clinical trials,
- We have documented experience in clinical diagnostics of leukemia and lymphoma.

4. **We declare the execution of the subject of request for the amount of …… EUR/USD (the total price for the execution of the order - all activities including all associated costs related to kits, reagents, consumables, management and other resources and operations needed to execute contracted work). The quote must include prices given in EUR or USD).**

5. **We declare the accumulated turnaround time (TAT) - time from arrival of the samples to the Vendor facility until the final report of …….. calendar days in total for Activities 1-8.**

Ordinal number		**Offered TAT** (If range of time given, the upper value will be taken for evaluation.)
Activity 1	Cytomorphological and cytochemical assessment of bone marrow and peripheral blood smears. Sponsor should be provided with a diagnostic report. – estimated/expected TAT around 1-3 days;	
Activity 2	Chromosome banding analysis (cytogenetic) and fluorescence in-situ hybridization (FISH) if applicable based on cytogenetic findings. Sponsor should be provided with a diagnostic report. – TAT 1-1.5 week;	
Activity 3	NGS analyses of the genes indicated in the table below, regions of interest are indicated in a separate column NGS should be performed with mean coverage above 1,000-fold and sensitivity of min 3%. Sponsor should be provided with a diagnostic report. – estimated/expected TAT around 10-12 days.	
Activity 4	Immunophenotyping analysis should be performed by flow cytometry (…), estimated/expected TAT around 2-4 days.	
Activity 5	Minimal/Measurable Residual Disease assessment (…), estimated/expected TAT around 10-12 days.	
Activity 6	Immunophenotyping of pSTAT5 in frozen blood samples (…),estimated/expected TAT around 2-5 days.	
Activity 7	Single cell RNA sequencing (…),Activity 1) estimated/expected TAT around 4-8 weeks.	
Activity 8	Single cell RNA sequencing validation (…),estimated/expected TAT around 8-10 weeks.	
	In total (accumulated TAT):	

6. We declare that we consider ourselves bound by this offer for the time of (minimum until 31st July 2023) …… .

7. We acknowledge that in the event of false statements, the offer shall be rejected.

APPENDICES:

1. …….
2. …….

…….. .....

Place and date Signature of the authorized person